Parkinson's Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors and Others), by Route of Adminstration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion) and by Distribution Channel for Hospital Pharmacy, Retail Pharmacy and Online Sales: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023
The report covers forecast and analysis for the Parkinsons disease therapeutics market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2023 based revenue (USD Billion). The study includes drivers and restraints for the Parkinsons disease therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Parkinsons disease therapeutics market on a global level.
In order to give the users of this report a comprehensive view on the Parkinsons disease therapeutics market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segment, route of administration segment and distribution channel segment is benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.
The study provides a decisive view on the Parkinsons disease therapeutics market by segmenting the market based on drug class, route of administration, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2023. Based on drug class the market is segmented into levodopa combination, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, anticholinergic drugs, catechol-o-methyltransferase (COMT) inhibitors and others. Based on rote of administration the market is segmented into the oral, transdermal, subcutaneous, and intestinal infusion. Based on distribution channel the market is segmented into hospital pharmacy, retail pharmacy, and online sales. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries. This segmentation includes demand for Parkinsons disease therapeutics market based on individual drug class, and distribution channel in all the regions and countries.
The report also includes detailed profiles of end players such as Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB, Inc., STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck Co., Inc., Impax Laboratories, Inc., and Others.
This report segments the global Parkinsons disease therapeutics market as follows:
Global Parkinsons Disease Therapeutics Market: Drug Class Segment Analysis
In order to give the users of this report a comprehensive view on the Parkinsons disease therapeutics market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segment, route of administration segment and distribution channel segment is benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.
The study provides a decisive view on the Parkinsons disease therapeutics market by segmenting the market based on drug class, route of administration, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2023. Based on drug class the market is segmented into levodopa combination, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, anticholinergic drugs, catechol-o-methyltransferase (COMT) inhibitors and others. Based on rote of administration the market is segmented into the oral, transdermal, subcutaneous, and intestinal infusion. Based on distribution channel the market is segmented into hospital pharmacy, retail pharmacy, and online sales. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries. This segmentation includes demand for Parkinsons disease therapeutics market based on individual drug class, and distribution channel in all the regions and countries.
The report also includes detailed profiles of end players such as Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB, Inc., STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck Co., Inc., Impax Laboratories, Inc., and Others.
This report segments the global Parkinsons disease therapeutics market as follows:
Global Parkinsons Disease Therapeutics Market: Drug Class Segment Analysis
- Levodopa Combination
- Dopamine Agonists
- Monoamine Oxidase B (Mao-B) Inhibitors
- Anticholinergic Drugs
- Catechol-O-Methyltransferase (Comt) Inhibitors
- Others
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
CHAPTER 1. INTRODUCTION
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Global Parkinsons disease therapeutics market, 2017 - 2023 (USD Billion)
2.2. Global Parkinsons disease therapeutics market: snapshot
CHAPTER 3. PARKINSONS DISEASE THERAPEUTICS MARKET- MARKET DYNAMICS
3.1. Introduction
3.2. Market Drivers
3.2.1. Global Parkinsons disease therapeutics market drivers: impact analysis
3.2.2. Increasing environmental factors genetic heredity
3.3. Market Restraints
3.3.1. Global Parkinsons disease therapeutics market restraints: impact analysis
3.3.2. Patent expiration of key branded drugs and side-effects associated with therapeutic drugs
3.4. Opportunities
3.4.1. Promising product pipeline represents the potential business development opportunities
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market Attractiveness Analysis
3.6.1. Market attractiveness analysis, by drug class segment
3.6.2. Market attractiveness analysis, by route of administration segment
3.6.3. Market attractiveness analysis, by distribution channel segment
3.6.4. Market attractiveness analysis, by regional segment
CHAPTER 4. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- COMPETITIVE LANDSCAPE
4.1. Company market share analysis
4.1.1. Global Parkinsons disease therapeutics market: company market share, 2017
4.2. Strategic development
4.2.1. Acquisitions mergers
4.2.2. New therapy launch
4.2.3. Agreements, partnerships, collaborations and joint ventures
4.2.4. Research and development and regional expansion
4.3. Price trend analysis
CHAPTER 5. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- DRUG CLASS SEGMENT ANALYSIS
5.1. Global Parkinsons disease therapeutics market: drug class overview
5.1.1. Global Parkinsons disease therapeutics market revenue share, by drug class, 2017 and 2023
5.2. Levodopa Combination
5.2.1. Global Parkinsons disease therapeutics market for levodopa combination, 2017 - 2023 (USD Billion)
5.3. Dopamine Agonists
5.3.1. Global Parkinsons disease therapeutics market for dopamine agonists, 2017 - 2023 (USD Billion)
5.4. Monoamine Oxidase B (MAO-B) Inhibitors
5.4.1. Global Parkinsons disease therapeutics market for monoamine oxidase B (MAO-B) Inhibitors, 2017 - 2023 (USD Billion)
5.5. Anticholinergic Drugs
5.5.1. Global Parkinsons disease therapeutics market for anticholinergic drugs, 2017 - 2023 (USD Billion)
5.6. Catechol-O-Methyltransferase (COMT) Inhibitors
5.6.1. Global Parkinsons disease therapeutics market for catechol-o-methyltransferase (COMT) inhibitors, 2017 - 2023 (USD Billion)
5.7. Others
5.7.1. Global Parkinsons disease therapeutics market for others, 2017 - 2023 (USD Billion)
CHAPTER 6. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- ROUTE OF ADMINISTRATION SEGMENT ANALYSIS
6.1. Global Parkinsons disease therapeutics market: route of administration overview
6.1.1. Global Parkinsons disease therapeutics market revenue share, by route of administration, 2017 and 2023
6.2. Oral
6.2.1. Global Parkinsons disease therapeutics market for oral, 2017 - 2023 (USD Billion)
6.3. Transdermal
6.3.1. Global Parkinsons disease therapeutics market for independent transdermal, 2017 - 2023 (USD Billion)
6.4. Subcutaneous
6.4.1. Global Parkinsons disease therapeutics market for subcutaneous, 2017 - 2023 (USD Billion)
6.5. Intestinal Infusion
6.5.1. Global Parkinsons disease therapeutics market for intestinal infusion, 2017 - 2023 (USD Billion)
CHAPTER 7. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- DISTRIBUTION CHANNEL SEGMENT ANALYSIS
7.1. Global Parkinsons disease therapeutics market: distribution channel overview
7.1.1. Global Parkinsons disease therapeutics market revenue share, by distribution channel, 2017 and 2023
7.2. Hospital Pharmacy
7.2.1. Global Parkinsons disease therapeutics market for hospital pharmacy, 2017 - 2023 (USD Billion)
7.3. Retail Pharmacy
7.3.1. Global Parkinsons disease therapeutics market for retail pharmacy, 2017 - 2023 (USD Billion)
7.4. Online Sales
7.4.1. Global Parkinsons disease therapeutics market for online sales, 2017 - 2023 (USD Billion)
CHAPTER 8. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- REGIONAL SEGMENT ANALYSIS
8.1. Global Parkinsons disease therapeutics market: regional overview
8.1.1. Global Parkinsons disease therapeutics market revenue share, by region, 2017 and 2023
8.2. North America
8.2.1. North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.2. North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.3. North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.2.4. U.S.
8.2.4.1. U.S. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.4.2. U.S. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.4.3. U.S. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.2.5. Rest of North America
8.2.5.1. Rest of North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.5.2. Rest of North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.5.3. Rest of North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3. Europe
8.3.1. Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.2. Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.3. Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.4. U.K.
8.3.4.1. U.K. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.4.2. U.K. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.4.3. U.K. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.5. Germany
8.3.5.1. Germany Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.5.2. Germany Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.5.3. Germany Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.6. France
8.3.6.1. France Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.6.2. France Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.6.3. France Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.7. Rest of Europe
8.3.7.1. Rest of Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.7.2. Rest of Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.7.3. Rest of Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.2. Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.3. Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.4. China
8.4.4.1. China Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.4.2. China Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.4.3. China Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.5. Japan
8.4.5.1. Japan Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.5.2. Japan Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.5.3. Japan Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.6. India
8.4.6.1. India Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.6.2. India Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.6.3. India Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.7. Rest of Asia Pacific
8.4.7.1. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.7.2. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.7.3. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5. Latin America
8.5.1. Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.2. Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.3. Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.4. Brazil
8.5.4.1. Brazil Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.4.2. Brazil Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.4.3. Brazil Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.5. Mexico
8.5.5.1. Mexico Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.5.2. Mexico Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.5.3. Mexico Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.6. Rest of Latin America
8.5.6.1. Rest of Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.6.2. Rest of Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.6.3. Rest of Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.2. Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.3. Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.4. Saudi Arabia
8.6.4.1. Saudi Arabia Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.4.2. Saudi Arabia Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.4.3. Saudi Arabia Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.5. UAE
8.6.5.1. UAE Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.5.2. UAE Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.5.3. UAE Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.6. South Africa
8.6.6.1. South Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.6.2. South Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.6.3. South Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.7. Rest of Middle East and Africa
8.6.7.1. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.7.2. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.7.3. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
CHAPTER 9. COMPANY PROFILE
9.1. Novartis AG
9.1.1. Overview
9.1.2. Financials
9.1.3. Therapy portfolio
9.1.4. Business strategy
9.1.5. Recent developments
9.2. F. Hoffmann-La Roche AG
9.2.1. Overview
9.2.2. Financials
9.2.3. Therapy portfolio
9.2.4. Business strategy
9.2.5. Recent developments
9.3. AbbVie, Inc.
9.3.1. Overview
9.3.2. Financials
9.3.3. Therapy portfolio
9.3.4. Business strategy
9.3.5. Recent developments
9.4. Teva Pharmaceutical Industries Ltd.
9.4.1. Overview
9.4.2. Financials
9.4.3. Therapy portfolio
9.4.4. Business strategy
9.4.5. Recent developments
9.5. UCB, Inc.
9.5.1. Overview
9.5.2. Financials
9.5.3. Therapy portfolio
9.5.4. Business strategy
9.5.5. Recent developments
9.6. STADA Arzneimittel AG
9.6.1. Overview
9.6.2. Financials
9.6.3. Therapy portfolio
9.6.4. Business strategy
9.6.5. Recent developments
9.7. GlaxoSmithKline Plc
9.7.1. Overview
9.7.2. Financials
9.7.3. Therapy portfolio
9.7.4. Business strategy
9.7.5. Recent developments
9.8. Valeant Pharmaceuticals International, Inc.
9.8.1. Overview
9.8.2. Financials
9.8.3. Therapy portfolio
9.8.4. Business strategy
9.8.5. Recent developments
9.9. Merck Co., Inc.
9.9.1. Overview
9.9.2. Financials
9.9.3. Therapy portfolio
9.9.4. Business strategy
9.9.5. Recent developments
9.10. Impax Laboratories, Inc.
9.10.1. Overview
9.10.2. Financials
9.10.3. Therapy portfolio
9.10.4. Business strategy
9.10.5. Recent developments
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Global Parkinsons disease therapeutics market, 2017 - 2023 (USD Billion)
2.2. Global Parkinsons disease therapeutics market: snapshot
CHAPTER 3. PARKINSONS DISEASE THERAPEUTICS MARKET- MARKET DYNAMICS
3.1. Introduction
3.2. Market Drivers
3.2.1. Global Parkinsons disease therapeutics market drivers: impact analysis
3.2.2. Increasing environmental factors genetic heredity
3.3. Market Restraints
3.3.1. Global Parkinsons disease therapeutics market restraints: impact analysis
3.3.2. Patent expiration of key branded drugs and side-effects associated with therapeutic drugs
3.4. Opportunities
3.4.1. Promising product pipeline represents the potential business development opportunities
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market Attractiveness Analysis
3.6.1. Market attractiveness analysis, by drug class segment
3.6.2. Market attractiveness analysis, by route of administration segment
3.6.3. Market attractiveness analysis, by distribution channel segment
3.6.4. Market attractiveness analysis, by regional segment
CHAPTER 4. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- COMPETITIVE LANDSCAPE
4.1. Company market share analysis
4.1.1. Global Parkinsons disease therapeutics market: company market share, 2017
4.2. Strategic development
4.2.1. Acquisitions mergers
4.2.2. New therapy launch
4.2.3. Agreements, partnerships, collaborations and joint ventures
4.2.4. Research and development and regional expansion
4.3. Price trend analysis
CHAPTER 5. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- DRUG CLASS SEGMENT ANALYSIS
5.1. Global Parkinsons disease therapeutics market: drug class overview
5.1.1. Global Parkinsons disease therapeutics market revenue share, by drug class, 2017 and 2023
5.2. Levodopa Combination
5.2.1. Global Parkinsons disease therapeutics market for levodopa combination, 2017 - 2023 (USD Billion)
5.3. Dopamine Agonists
5.3.1. Global Parkinsons disease therapeutics market for dopamine agonists, 2017 - 2023 (USD Billion)
5.4. Monoamine Oxidase B (MAO-B) Inhibitors
5.4.1. Global Parkinsons disease therapeutics market for monoamine oxidase B (MAO-B) Inhibitors, 2017 - 2023 (USD Billion)
5.5. Anticholinergic Drugs
5.5.1. Global Parkinsons disease therapeutics market for anticholinergic drugs, 2017 - 2023 (USD Billion)
5.6. Catechol-O-Methyltransferase (COMT) Inhibitors
5.6.1. Global Parkinsons disease therapeutics market for catechol-o-methyltransferase (COMT) inhibitors, 2017 - 2023 (USD Billion)
5.7. Others
5.7.1. Global Parkinsons disease therapeutics market for others, 2017 - 2023 (USD Billion)
CHAPTER 6. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- ROUTE OF ADMINISTRATION SEGMENT ANALYSIS
6.1. Global Parkinsons disease therapeutics market: route of administration overview
6.1.1. Global Parkinsons disease therapeutics market revenue share, by route of administration, 2017 and 2023
6.2. Oral
6.2.1. Global Parkinsons disease therapeutics market for oral, 2017 - 2023 (USD Billion)
6.3. Transdermal
6.3.1. Global Parkinsons disease therapeutics market for independent transdermal, 2017 - 2023 (USD Billion)
6.4. Subcutaneous
6.4.1. Global Parkinsons disease therapeutics market for subcutaneous, 2017 - 2023 (USD Billion)
6.5. Intestinal Infusion
6.5.1. Global Parkinsons disease therapeutics market for intestinal infusion, 2017 - 2023 (USD Billion)
CHAPTER 7. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- DISTRIBUTION CHANNEL SEGMENT ANALYSIS
7.1. Global Parkinsons disease therapeutics market: distribution channel overview
7.1.1. Global Parkinsons disease therapeutics market revenue share, by distribution channel, 2017 and 2023
7.2. Hospital Pharmacy
7.2.1. Global Parkinsons disease therapeutics market for hospital pharmacy, 2017 - 2023 (USD Billion)
7.3. Retail Pharmacy
7.3.1. Global Parkinsons disease therapeutics market for retail pharmacy, 2017 - 2023 (USD Billion)
7.4. Online Sales
7.4.1. Global Parkinsons disease therapeutics market for online sales, 2017 - 2023 (USD Billion)
CHAPTER 8. GLOBAL PARKINSONS DISEASE THERAPEUTICS MARKET- REGIONAL SEGMENT ANALYSIS
8.1. Global Parkinsons disease therapeutics market: regional overview
8.1.1. Global Parkinsons disease therapeutics market revenue share, by region, 2017 and 2023
8.2. North America
8.2.1. North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.2. North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.3. North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.2.4. U.S.
8.2.4.1. U.S. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.4.2. U.S. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.4.3. U.S. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.2.5. Rest of North America
8.2.5.1. Rest of North America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.2.5.2. Rest of North America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.2.5.3. Rest of North America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3. Europe
8.3.1. Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.2. Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.3. Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.4. U.K.
8.3.4.1. U.K. Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.4.2. U.K. Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.4.3. U.K. Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.5. Germany
8.3.5.1. Germany Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.5.2. Germany Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.5.3. Germany Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.6. France
8.3.6.1. France Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.6.2. France Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.6.3. France Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.3.7. Rest of Europe
8.3.7.1. Rest of Europe Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.3.7.2. Rest of Europe Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.3.7.3. Rest of Europe Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.2. Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.3. Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.4. China
8.4.4.1. China Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.4.2. China Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.4.3. China Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.5. Japan
8.4.5.1. Japan Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.5.2. Japan Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.5.3. Japan Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.6. India
8.4.6.1. India Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.6.2. India Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.6.3. India Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.4.7. Rest of Asia Pacific
8.4.7.1. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.4.7.2. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.4.7.3. Rest of Asia Pacific Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5. Latin America
8.5.1. Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.2. Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.3. Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.4. Brazil
8.5.4.1. Brazil Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.4.2. Brazil Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.4.3. Brazil Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.5. Mexico
8.5.5.1. Mexico Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.5.2. Mexico Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.5.3. Mexico Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.5.6. Rest of Latin America
8.5.6.1. Rest of Latin America Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.5.6.2. Rest of Latin America Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.5.6.3. Rest of Latin America Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.2. Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.3. Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.4. Saudi Arabia
8.6.4.1. Saudi Arabia Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.4.2. Saudi Arabia Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.4.3. Saudi Arabia Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.5. UAE
8.6.5.1. UAE Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.5.2. UAE Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.5.3. UAE Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.6. South Africa
8.6.6.1. South Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.6.2. South Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.6.3. South Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
8.6.7. Rest of Middle East and Africa
8.6.7.1. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by drug class, 2017 - 2023 (USD Billion)
8.6.7.2. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by route of administration, 2017 - 2023 (USD Billion)
8.6.7.3. Rest of Middle East and Africa Parkinsons disease therapeutics market revenue, by distribution channel, 2017 - 2023 (USD Billion)
CHAPTER 9. COMPANY PROFILE
9.1. Novartis AG
9.1.1. Overview
9.1.2. Financials
9.1.3. Therapy portfolio
9.1.4. Business strategy
9.1.5. Recent developments
9.2. F. Hoffmann-La Roche AG
9.2.1. Overview
9.2.2. Financials
9.2.3. Therapy portfolio
9.2.4. Business strategy
9.2.5. Recent developments
9.3. AbbVie, Inc.
9.3.1. Overview
9.3.2. Financials
9.3.3. Therapy portfolio
9.3.4. Business strategy
9.3.5. Recent developments
9.4. Teva Pharmaceutical Industries Ltd.
9.4.1. Overview
9.4.2. Financials
9.4.3. Therapy portfolio
9.4.4. Business strategy
9.4.5. Recent developments
9.5. UCB, Inc.
9.5.1. Overview
9.5.2. Financials
9.5.3. Therapy portfolio
9.5.4. Business strategy
9.5.5. Recent developments
9.6. STADA Arzneimittel AG
9.6.1. Overview
9.6.2. Financials
9.6.3. Therapy portfolio
9.6.4. Business strategy
9.6.5. Recent developments
9.7. GlaxoSmithKline Plc
9.7.1. Overview
9.7.2. Financials
9.7.3. Therapy portfolio
9.7.4. Business strategy
9.7.5. Recent developments
9.8. Valeant Pharmaceuticals International, Inc.
9.8.1. Overview
9.8.2. Financials
9.8.3. Therapy portfolio
9.8.4. Business strategy
9.8.5. Recent developments
9.9. Merck Co., Inc.
9.9.1. Overview
9.9.2. Financials
9.9.3. Therapy portfolio
9.9.4. Business strategy
9.9.5. Recent developments
9.10. Impax Laboratories, Inc.
9.10.1. Overview
9.10.2. Financials
9.10.3. Therapy portfolio
9.10.4. Business strategy
9.10.5. Recent developments
